kabutan

KYORIN Pharma Surges on License Agreement with France's Biodol for Neuropathic Pain Drug Candidate

Wed Apr 1, 2026 1:07 pm JST Catalyst

KYORIN Pharmaceutical Co.,Ltd. <4569> rose sharply, rebounding for the first time in three days. After the close of trading on the 31st, the company announced it had signed a license agreement with French drug discovery venture Biodol Therapeutics for the neuropathic pain treatment drug candidate "BDT272," which is being viewed as positive news.

"BDT272" is a compound believed to exert effective analgesic effects by inhibiting FLT3 (receptor tyrosine kinase family), which is deeply involved in the onset and persistence of pain, including neuropathic pain. Under this license agreement, KYORIN Pharma has acquired exclusive development, manufacturing, and commercialization rights in Japan, South Korea, and Taiwan. In consideration, the company will pay Biodol up to 79 million euros in total as upfront payments and milestone payments, as well as royalties based on net sales.

Source: MINKABU PRESS

Related Articles